BioCryst Pharma (BCRX) Posts Narrower than Expected Q1 Loss of 13c/Share; Reaffirms
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.99 +0.71%
EPS Growth %: -43.8%
Financial Fact:
Total expenses: 17M
Today's EPS Names:
RCBC, GASS, YSG, More
EPS Growth %: -43.8%
Financial Fact:
Total expenses: 17M
Today's EPS Names:
RCBC, GASS, YSG, More
Join SI Premium – FREE
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q1 EPS of ($0.13), $0.13 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $5.9 million.
BioCryst Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
BioCryst Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sprinklr (CXM) Tops Q2 EPS by 1c, Offers Guidance
- Bernstein SocGen: 'We view AI as a significant long-term opportunity for UnitedHealth Group (UNH)'
- Goldman Sachs favors equities over credit as late-cycle risks build
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
